|
1.
|
Morgensztern D and McLeod HL:
PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer
Drugs. 16:797–803. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Yap TA, Garrett MD, Walton MI, Raynaud F,
de Bono JS and Workman P: Targeting the PI3K-AKT-mTOR pathway:
progress, pitfalls, and promises. Curr Opin Pharmacol. 8:393–412.
2008. View Article : Google Scholar
|
|
3.
|
LoPiccolo J, Blumenthal GM, Bernstein WB
and Dennis PA: Targeting the PI3K/Akt/mTOR pathway: effective
combinations and clinical considerations. Drug Resist Updat.
11:32–50. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Song G, Ouyang G and Bao S: The activation
of Akt/PKB signaling pathway and cell survival. J Cell Mol Med.
9:59–71. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
DeFeo-Jones D, Barnett SF, Fu S, et al:
Tumor cell sensitization to apoptotic stimuli by selective
inhibition of specific Akt/PKB family members. Mol Cancer Ther.
4:271–279. 2005.PubMed/NCBI
|
|
6.
|
Qiao M, Sheng S and Pardee AB: Metastasis
and AKT activation. Cell Cycle. 7:2991–2996. 2008. View Article : Google Scholar
|
|
7.
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Brader S and Eccles SA: Phosphoinositide
3-kinase signalling pathways in tumor progression, invasion and
angiogenesis. Tumori. 90:2–8. 2004.
|
|
9.
|
Stambolic V, Suzuki A, de la Pompa JL, et
al: Negative regulation of PKB/Akt-dependent cell survival by the
tumor suppressor PTEN. Cell. 95:29–39. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Akca H, Demiray A, Tokgun O and Yokota J:
Invasiveness and anchorage independent growth ability augmented by
PTEN inactivation through the PI3K/AKT/NFκB pathway in lung cancer
cells. Lung Cancer. 73:302–309. 2011.PubMed/NCBI
|
|
11.
|
Carver BS, Chapinski C, Wongvipat J, et
al: Reciprocal feedback regulation of PI3K and androgen receptor
signaling in PTEN-deficient prostate cancer. Cancer Cell.
19:575–586. 2011. View Article : Google Scholar
|
|
12.
|
Cully M, You H, Levine AJ and Mak TW:
Beyond PTEN mutations: the PI3K pathway as an integrator of
multiple inputs during tumorigenesis. Nat Rev Cancer. 6:184–192.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Moasser MM: The oncogene HER2: its
signaling and transforming functions and its role in human cancer
pathogenesis. Oncogene. 26:6469–6487. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Baselga J and Swain SM: Novel anticancer
targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer.
9:463–475. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Grille SJ, Bellacosa A, Upson J, et al:
The protein kinase Akt induces epithelial mesenchymal transition
and promotes enhanced motility and invasiveness of squamous cell
carcinoma lines. Cancer Res. 63:2172–2178. 2003.PubMed/NCBI
|
|
16.
|
Toker A and Yoeli-Lerner M: Akt signaling
and cancer: surviving but not moving on. Cancer Res. 66:3963–3966.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Yoeli-Lerner M and Toker A: Akt/PKB
signaling in cancer: a function in cell motility and invasion. Cell
Cycle. 5:603–605. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Gagnon V, St-Germain ME, Parent S and
Asselin E: Akt activity in endometrial cancer cells: Regulation of
cell survival through cIAP-1. Int J Oncol. 23:803–810.
2003.PubMed/NCBI
|
|
19.
|
Cross DA, Alessi DR, Cohen P, Andjelkovich
M and Hemmings BA: Inhibition of glycogen synthase kinase-3 by
insulin mediated by protein kinase B. Nature. 378:785–789. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Luo J: Glycogen synthase kinase 3beta
(GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett.
273:194–200. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Morin PJ: beta-catenin signaling and
cancer. Bioessays. 21:1021–1030. 1999. View Article : Google Scholar
|
|
22.
|
Guturi KK, Mandal T, Chatterjee A, et al:
Mechanism of beta-catenin-mediated transcriptional regulation of
epidermal growth factor receptor expression in glycogen synthase
kinase 3 beta-inactivated prostate cancer cells. J Biol Chem.
287:18287–18296. 2012. View Article : Google Scholar
|
|
23.
|
Hannigan GE, McDonald PC, Walsh MP and
Dedhar S: Integrin-linked kinase: not so ‘pseudo’ after all.
Oncogene. 30:4375–4385. 2011.
|
|
24.
|
Acconcia F, Barnes CJ, Singh RR, Talukder
AH and Kumar R: Phosphorylation-dependent regulation of nuclear
localization and functions of integrin-linked kinase. Proc Natl
Acad Sci USA. 104:6782–6787. 2007. View Article : Google Scholar
|
|
25.
|
Wani AA, Jafarnejad SM, Zhou J and Li G:
Integrin-linked kinase regulates melanoma angiogenesis by
activating NF-kappaB/interleukin-6 signaling pathway. Oncogene.
30:2778–2788. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Tan C, Cruet-Hennequart S, Troussard A, et
al: Regulation of tumor angiogenesis by integrin-linked kinase
(ILK). Cancer Cell. 5:79–90. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Taylor CJ, Qiao J, Colon NC, Schlegel C,
Josifi E and Chung DH: Integrin-linked kinase regulates phosphatase
and tensin homologue activity to promote tumorigenesis in
neuroblastoma cells. Surgery. 150:162–168. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Jung S, Li C, Jeong D, et al: Oncogenic
function of p34SEI-1 via NEDD41 mediated PTEN
ubiquitination/degradation and activation of the PI3K/AKT pathway.
Int J Oncol. 43:1587–1595. 2013.
|
|
29.
|
Wang X, Trotman LC, Koppie T, et al:
NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell.
128:129–139. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Amodio N, Scrima M, Palaia L, et al:
Oncogenic role of the E3 ubiquitin ligase NEDD4-1, a PTEN negative
regulator, in non-small-cell lung carcinomas. Am J Pathol.
177:2622–2634. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Hayashi R, Goto Y, Ikeda R, Yokoyama KK
and Yoshida K: CDCA4 is an E2F transcription factor family-induced
nuclear factor that regulates E2F-dependent transcriptional
activation and cell proliferation. J Biol Chem. 281:35633–35648.
2006. View Article : Google Scholar
|
|
32.
|
Hsu SI, Yang CM, Sim KG, Hentschel DM,
O’Leary E and Bonventre JV: TRIP-Br: a novel family of PHD zinc
finger- and bromodomain-interacting proteins that regulate the
transcriptional activity of E2F-1/DP-1. EMBO J. 20:2273–2285. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Hong SW, Kim CJ, Park WS, et al:
p34SEI-1 inhibits apoptosis through the stabilization of
the X-linked inhibitor of apoptosis protein: p34SEI-1 as
a novel target for anti-breast cancer strategies. Cancer Res.
69:741–746. 2009.
|
|
34.
|
Li Y, Nie CJ, Hu L, et al:
Characterization of a novel mechanism of genomic instability
involving the SEI1/SET/NM23H1 pathway in esophageal cancers. Cancer
Res. 70:5695–5705. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Tang DJ, Hu L, Xie D, et al: Oncogenic
transformation by SEI-1 is associated with chromosomal instability.
Cancer Res. 65:6504–6508. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Van Themsche C, Leblanc V, Parent S and
Asselin E: X-linked inhibitor of apoptosis protein (XIAP) regulates
PTEN ubiquitination, content, and compartmentalization. J Biol
Chem. 284:20462–20466. 2009.PubMed/NCBI
|
|
37.
|
Mehrotra S, Languino LR, Raskett CM,
Mercurio AM, Dohi T and Altieri DC: IAP regulation of metastasis.
Cancer Cell. 17:53–64. 2010. View Article : Google Scholar
|
|
38.
|
Arias AM: Epithelial mesenchymal
interactions in cancer and development. Cell. 105:425–431. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Knuefermann C, Lu Y, Liu B, et al:
HER2/PI-3K/Akt activation leads to a multidrug resistance in human
breast adenocarcinoma cells. Oncogene. 22:3205–3212. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Xing X, Wang SC, Xia W, et al: The ets
protein PEA3 suppresses HER-2/neu overexpression and inhibits
tumorigenesis. Nat Med. 6:189–195. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Yuen HF, McCrudden CM, Chan KK, et al: The
role of Pea3 group transcription factors in esophageal squamous
cell carcinoma. Am J Pathol. 179:992–1003. 2011. View Article : Google Scholar : PubMed/NCBI
|
